FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars
MoonLake Clears A Key Regulatory Hurdle, And Shares Rocket
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?
Da Silva Jorge Santos Sells 98,127 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 6% – Should You Sell?
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up After Analyst Upgrade
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?
Avoro Capital Advisors LLC Cuts Stock Position in MoonLake Immunotherapeutics $MLTX
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Hold” from Analysts
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday
MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal
MoonLake Immunotherapeutics Investor Day: HS BLA on Track, axSpA Phase 2 Data Highlights Imaging Wins
MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript
MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
Principal Financial Group Inc. Invests $509,000 in MoonLake Immunotherapeutics $MLTX
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
BioTech Breakout: MoonLake Up 30% On FDA Wins
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
MoonLake Immunotherapeutics (NASDAQ:MLTX) versus Nuvation Bio (NYSE:NUVB) Critical Review
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 9.6% – Should You Buy?
MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission
MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars
MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day
Contact Levi & Korsinsky by December 15, 2025 Deadline to Join Class Action Against MoonLake Immunotherapeutics(MLTX)
MLTX DEADLINE ALERT: Hagens Berman Alerts MoonLake (MLTX) Investors to Today's Lead Plaintiff Deadline in Securities Class Action
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
DEADLINE ALERT for MLTX, BAX, and JHX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm
Portnoy Law Firm Announces Class Action on Behalf of Moonlake Immunotherapeutics, Inc. Investors
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
MLTX FINAL DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit - Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge
MLTX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important December 15 Deadline in Securities Class Action – MLTX
MLTX DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that MoonLake Investors Have Opportunity to Lead Class Action Lawsuit
MLTX SECURITIES LAWSUIT: MoonLake Immunotherapeutics Investors Are Notified to Contact BFA Law Before Tomorrow's December 15 Class Action Deadline
MLTX 2-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit – Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms
MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm Before December 15th
MLTX FRAUD UPDATE: Important MoonLake Immunotherapeutics Securities Fraud Class Action Deadline is Approaching for Investors – Contact BFA Law before December 15
Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
MoonLake Immunotherapeutics Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – MLTX
MLTX Deadline: MLTX Investors with Losses in Excess of $100K Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit
MLTX DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important December 15 Deadline in Securities Class Action - MLTX